Preclinical studies of a Pro-antibody-drug conjugate designed to selectively target EGFR-overexpressing tumors with improved therapeutic efficacy

Antibody-drug conjugates (ADCs) have exhibited potent clinical benefits in cancer therapy. However, development of ADCs against epidermal growth factor receptor (EGFR) has limitations because of wide expression of EGFR in both normal and tumor tissues. Previously, we developed an anti-EGFR protease-...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:MAbs
Main Authors: Yang, Yun, Guo, Qingcheng, Chen, Xi, Zhang, Junjie, Guo, Huaizu, Qian, Weizhu, Hou, Sheng, Dai, Jianxin, Li, Bohua, Guo, Yajun, Wang, Hao
Formato: Artigo
Idioma:Inglês
Publicado em: Taylor & Francis 2016
Assuntos:
Reports
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4966596/
https://ncbi.nlm.nih.gov/pubmed/26760045
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/19420862.2015.1127491
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados